ロード中...
Review of the Treatment of Restless Legs Syndrome: Focus on Gabapentin Enacarbil
The FDA approved gabapentin enacarbil in 2011 as the first non-dopaminergic agent for the treatment of restless legs syndrome (RLS) symptoms. Although gabapentin enacarbil is a pro-drug of gabapentin, its pharmacokinetics differ. Absorption of gabapentin enacarbil is more predictable, and inter-pati...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Libertas Academica
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3619699/ https://ncbi.nlm.nih.gov/pubmed/23650473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/JCNSD.S9107 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|